ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.
Abou-Alfa, G Qin, S Ryoo, B Lu, S Yen, C Feng, Y Lim, H Izzo, F Colombo, M Sarker, D
Abou-Alfa, G
Qin, S
Ryoo, B
Lu, S
Yen, C
Feng, Y
Lim, H
Izzo, F
Colombo, M
Sarker, D
Citations
Altmetric:
Abstract
Arginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting enzyme. ADI-PEG 20 is a cloned arginine degrading enzyme - arginine deiminase - conjugated with polyethylene glycol. The goal of this study was to evaluate this agent as a potential novel therapeutic for HCC after first line systemic therapy.
Description
Date
2018-04-05
Publisher
Collections
Keywords
Type
Article
Citation
ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. 2018, Ann Oncol